


example, on page 123, lines 1-20. Support for use in the detection of lung cancer is provided throughout the specification including, for example, on page 148, lines 14-15, and support for specific biological samples is provided, for example, on page 122, lines 21-22.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**Version With Markings to Show Changes Made.**" Applicants respectfully submit that all claims remaining in the application are now clearly allowable. Favorable consideration and a Notice of Allowance are earnestly solicited. Applicants' attorney wishes to express her willingness to engage in a telephone interview to further the status of this application if any further concerns need to be addressed.

Respectfully submitted,  
Tongtong Wang et al.  
Seed Intellectual Property Law Group PLLC

  
\_\_\_\_\_  
Carol D. Laherty, Ph.D.  
Registration No. 51,909

CDL:sd

Enclosure:  
Postcard

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

D:\NrPortbl\iManage\SANDID\300460\_1.DOC

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

6. (Amended) A method for detecting the presence of a cancer in a patient, comprising the steps of:

- (a) obtaining a biological sample from the patient;
- (b) contacting the biological sample with a binding agent that binds to a polypeptide comprising at least 10 contiguous amino acid residues of a polypeptide encoded by the polynucleotide sequence of SEQ ID NO:808 of claim 2;
- (c) detecting in the sample an amount of polypeptide that binds to the binding agent; and
- (d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient.